Tumor treating fields (TTFs) have been in use for more than a decade as a therapy for glioma patients. The treatment works by placing arrays of transducers on the scalp that deliver non-ionizing electromagnetic waves at specific frequencies. These waves interfere with cancer cell division, slowing or even halting tumor growth.
Unlike systemic treatments such as chemotherapy or radiation, TTFs are localized, targeting the tumor directly while sparing surrounding healthy tissue from significant damage. To be effective, the device is typically worn for at least 18 hours per day—a commitment that can be difficult for many patients.
Dr. Katherine Peters of Duke University’s Preston Robert Tisch Brain Tumor Center notes that one ongoing challenge with TTFs is patient adoption, given the demands of daily use. Still, she believes the therapy should remain part of the treatment landscape, with additional clinical trials underway to assess its impact further. Meanwhile, Dr. Kathryn Nevel, a neurologist and neuro-oncologist at Indiana University School of Medicine, raises an important question: how long should patients continue using tumor-treating fields once they begin?
